Alkem aims to expand access to treatment with its affordable pertuzumab biosimilar that meets global standards and is backed by trusted scienceAlkem Laboratories Ltd. today announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer. Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab. In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator. By bringing an affordable pertuzumab biosimilar, backed by research, regulatory-compliant manufacturing, and strong oncology distribution network, Alkem strives to ensure scientific credibility and improved accessibility. Alkem has a growing portfolio of oncology drugs with key products being cetuximab biosimilar, denosumab biosimilar, bevacizumab biosimilar, and romiplostim biosimilar, among others.